| Literature DB >> 35891146 |
Lene Dahl Lund1, Mette Margrethe Løwe1, Oliver Hendricks2,3, Karen Schreiber2,3, Bente Glintborg4,5, Randi Petersen2, Christiane Plischke2, Willy Fick2, Jette Primdahl2,3,6.
Abstract
People with inflammatory arthritis (IA) treated with immunosuppressive disease-modifying anti-rheumatic drugs (DMARDs) were initially considered to have an increased risk of severe illness from the SARS-CoV-2 virus compared to the general population. The aim of this study was to explore how people with IA experienced restrictions during the pandemic and the possible impact of vaccination on their protection against COVID-19 and their everyday lives. Nineteen people with IA were interviewed in May-August 2021; shortly thereafter they were enrolled in the Danish national COVID-19 vaccination programme. Concurrently, society gradually reopened after a national complete lockdown. The analysis was inspired by inductive qualitative content analysis. Participants expressed a lack of targeted information on the specific risk associated with IA if they contracted COVID-19. They had to define their own level of daily-life restrictions to protect themselves and their families. They were impacted by inconsistent announcements by the authorities, and some expressed concerns regarding the potential influence of DMARDs on vaccine effectiveness. A societal spirit of being "in this together" emerged through the lockdown, and some were concerned that the reduced level of restrictions in the reopened society would put them at higher risk of a COVID-19 infection and force them to continue self-isolating.Entities:
Keywords: COVID-19; DMARDs; inflammatory arthritis; qualitative research methods; vaccination
Year: 2022 PMID: 35891146 PMCID: PMC9318035 DOI: 10.3390/vaccines10070982
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Interview guide.
|
What has the COVID-19 pandemic meant to you? What are your thoughts about the risk of you being infected with COVID-19? What medication/treatment do you take for your arthritis? What are your considerations regarding vaccination against COVID-19? What are your thoughts about the present reopening of society? |
The steps in the inductive qualitative content-analysis process.
| Step 1: All audio-recorded interviews, which constituted the unit of analysis, were listened to while reading and adjusting each transcript simultaneously. |
| Step 2: All transcripts were read again while taking reflective notes and meaning units of importance to the aim of the study were identified. |
| Step 3: The identified meaning units were condensed and coded according to the manifest content. |
| Step 4: Codes were grouped into categories based on differences and similarities. This abstraction process was performed in collaboration with a co-researcher. |
| Step 5: Authors 1 and 2 arranged a workshop for the two patient research partners. They were introduced to a broad range of meaning units within all categories followed by questions for reflection, e.g., “What is at stake for the participants in this situation?” and “Are there other aspects that can give rise to reflection?” Their reflections were audio recorded and notes were taken along the way to support the analysis process. |
| Step 6: After interpretation of the categories among all authors, they were condensed into five themes. These themes express the underlying meaning of the material on an interpretative level and, thus, the latent content of the material. |
Characteristics of the participants.
| Participant Number | Sex | Age | Living Alone/ | Working | Diagnosis | Medical Treatment | Vaccination |
|---|---|---|---|---|---|---|---|
| 1 | m | 50–59 | Alone | No | PSA | cDMARD | Pfizer-BioNTech |
| 2 | f | 50–59 | Alone | Yes | SPA | bDMARD | Pfizer-BioNTech |
| 3 | m | 50–59 | Alone | No | MB | None | Pfizer-BioNTech |
| 4 | f | 50–59 | Partner | Yes | MB | None | Pfizer-BioNTech |
| 5 | m | 50–59 | Partner | Yes | RA | cDMARD | Pfizer-BioNTech |
| 6 | f | 60–69 | Partner | No | RA | bDMARD | Pfizer-BioNTech |
| 7 | f | 50–59 | Partner | Yes | RA | cDMARD | Pfizer-BioNTech |
| 8 | f | 50–59 | Partner | Yes | RA | cDMARD | Pfizer-BioNTech |
| 9 | m | 60–69 | Alone | No | PSA | bDMARD | Pfizer-BioNTech |
| 10 | m | 60–69 | Partner | Yes | RA | bDMARD | Pfizer-BioNTech |
| 11 | f | 60–69 | Partner | No | RA | cDMARD | Pfizer-BioNTech |
| 12 | f | 50–59 | Alone | Yes | RA | cDMARD | None |
| 13 | f | 20–29 | Partner | Yes | JIA | bDMARD | None |
| 14 | m | 40–49 | Partner | No | PSA | None | Pfizer-BioNTech |
| 15 | f | 40–49 | Partner | Yes | RA | None | Pfizer-BioNTech |
| 16 | f | 40–49 | Partner | Yes | JIA | None | Pfizer-BioNTech |
| 17 | m | 30–39 | Partner | Yes | SPA | bDMARD | Moderna |
| 18 | f | 30–39 | Alone | No | SPA | bDMARD | Pfizer-BioNTech |
| 19 | f | 30–39 | Partner | Yes | RA | cDMARD | Moderna |
m = male, f = female, PSA = psoriatic arthritis, SpA = spondyloarthropathy, RA = rheumatoid arthritis, JIA = juvenile arthritis, MB = Morbus–Bechterew, cDMARD = conventional disease-modifying anti-rheumatic drug, bDMARD = biological disease-modifying anti-rheumatic drug.
Emerging themes.
| Theme 1 | Theme 2 | Theme 3 | Theme 4 | Theme 5 |
|---|---|---|---|---|
| “Changing and divergent information” | “Individual interpretation of own risk” | “Impact on everyday life” | “Position in society and the vaccination programme” | “Reopening is somehow harder than lock-down” |